ACOT9

Across TCGA pan-cancer cohorts, ACOT9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACOT9 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ACOT9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACOT9 expression acts as an unfavorable survival marker.

LSCC, CCRCC, and PDAC are the cancer types where ACOT9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.541	0.843	<.001	45	view →
CCRCC	DFS	Quartile	II,III,IV	0.494	0.948	.001	36	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	6	view →
HNSC	OS	Tertile	II,III,IV	0.941	1.000	.031	4	view →
UCEC	OS	Median	III,IV	0.333	0.904	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACOT9–LSCC (DFS)

Open the LSCC breakdown →